Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Powder Clear all
Terminated Phase 1Phase 2 Interventional Results available

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT05086315
View directory record Official record
Conditions
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Interventions
SAR443579
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

NCT02635776
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
49
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

NCT00626249
View directory record Official record
Conditions
Mild Nephropathy, Moderate Nephropathy, Diabetes Mellitus
Interventions
Technosphere Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Minneapolis, Minnesota • Omaha, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

NCT00819585
View directory record Official record
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 30, 2026, 10:36 PM EDT
Recruiting Phase 3 Interventional

A Study of Sepiapterin in Participants With Phenylketonuria (PKU)

NCT06302348
View directory record Official record
Conditions
Phenylketonuria
Interventions
Sepiapterin
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Up to 9 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolism and Absorption of Anthocyanins From Extract and Whole Blueberry Powder Confections in Healthy Adults

NCT04329962
View directory record Official record
Conditions
Healthy Diet, Nutrition Aspect of Cancer
Interventions
Blueberry Powder Food Product, Dietary Intervention, Questionnaire Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

NCT01667679
View directory record Official record
Conditions
Migraine, Headaches
Interventions
100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally, OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

GutMe!: IBS and Collagen Protein Powder an Interventional Study

NCT04245254
View directory record Official record
Conditions
Irritable Bowel Syndrome, Irritable Bowel, Irrit
Interventions
Collagen Protien Powder
Dietary Supplement
Lead sponsor
ProofPilot
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Antibiotic Elution in Total Knee Arthroplasty

NCT03928522
View directory record Official record
Conditions
Total Knee Replacement
Interventions
hand mixed vancomycin, hand mixed tobramycin, pre-mixed tobramycin
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)

NCT02410902
View directory record Official record
Conditions
Autism
Interventions
CM-AT, PLACEBO
Drug
Lead sponsor
Curemark
Industry
Eligibility
3 Years to 8 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

NCT01120691
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, NVA237, tiotropium, Salbutamol/albuterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure

NCT02935946
View directory record Official record
Conditions
Deglutition Disorders, Respiratory Aspiration
Interventions
Cold Liquid Barium
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
36 Weeks to 43 Weeks
Enrollment
4,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 30, 2026, 10:36 PM EDT
Recruiting Phase 4 Interventional

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

NCT06941870
View directory record Official record
Conditions
Factor VIII Deficiency
Interventions
Efanesoctocog alfa
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza

NCT02014649
View directory record Official record
Conditions
Influenza
Interventions
20 mg laninamivir octanoate, Placebo, 40 mg laninamivir octanoate
Drug
Lead sponsor
Biota Scientific Management Pty Ltd
Industry
Eligibility
5 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 30, 2026, 10:36 PM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

NCT01932970
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Alhambra, California • Azusa, California • Bakersfield, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 30, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT07333183
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
inhaled mosliciguat, Dry Powder Inhaler
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)

NCT06733688
View directory record Official record
Conditions
Healthy
Interventions
Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

NCT01519661
View directory record Official record
Conditions
Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions
TBM100
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Little Rock, Arkansas • Denver, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

A Study of NT 201 Doses in the Treatment of Platysma Prominence

NCT05773053
View directory record Official record
Conditions
Platysma Prominence
Interventions
NT 201, NT 201 Placebo
Drug
Lead sponsor
Merz Aesthetics GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Aventura, Florida • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 30, 2026, 10:36 PM EDT
Recruiting Phase 1 Interventional

Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum

NCT07401277
View directory record Official record
Conditions
Actinic Keratoses
Interventions
5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH)
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

NCT00603746
View directory record Official record
Conditions
Asthma
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
94
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 30, 2026, 10:36 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study on the Effects of Soulera Herbal Blend Intake on Chronic Stress in Healthy Adults

NCT01299402
View directory record Official record
Conditions
Chronic Stress
Interventions
Soulera Herbal Blend, Placebo
Dietary Supplement
Lead sponsor
Joseph Pergolizzi, MD
Industry
Eligibility
21 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

NCT00721344
View directory record Official record
Conditions
Healthy Subjects
Interventions
Technosphere Inhalation Powder (FDKP), Moxifloxacin, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 30, 2026, 10:36 PM EDT